Evidence map›Paper›PMID 33761872›Full record

ArticleBMC genomics2021

Whole-genome analysis of probiotic product isolates reveals the presence of genes related to antimicrobial resistance, virulence factors, and toxic metabolites, posing potential health risks.

Ying Wang, Qian Liang, Bian Lu, Hong Shen, Shuyan Liu, Ya Shi, Sebastian Leptihn, Hong Li, Jin Wei, Chengzhi Liu and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Whole-Genome-Guided Functional Characterization ofFoods (Basel, Switzerland) · 2026
    Article
  9. MitigatingMicroorganisms · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Frontiers in microbiology · 2026
    Article
  14. Unveiling the probiotic potential ofAIMS microbiology · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Ying Wang *Key laboratory of Microbial technology and Bioinformatics of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou, 310012, Zhejiang, China.
Qian Liang *Key laboratory of Microbial technology and Bioinformatics of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou, 310012, Zhejiang, China.
Bian Lu *Xiaoshan Center for Disease Control and Prevention, Hangzhou, 311201, Zhejiang, China.
Hong ShenNMPA Key laboratory for Testing and Risk Warning of Pharmaceutical Microbiology, Biological Inspection Department, Zhejiang Institute for Food and Drug Control, Hangzhou, 310052, Zhejiang, China.
Shuyan LiuDalian Customs District, Dalian, 116001, Liaoning, China.
Ya ShiKey laboratory of Microbial technology and Bioinformatics of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou, 310012, Zhejiang, China.
Sebastian LeptihnZhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
Hong LiChina National Accreditation Institute for Conformity Assessment, Beijing, 100062, China.
Jin WeiNordkapp Medical Group, Hangzhou, 311121, Zhejiang, China.
Chengzhi LiuKey laboratory of Microbial technology and Bioinformatics of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou, 310012, Zhejiang, China.
Hailong XiaoHangzhou Institute for Food and Drug Control, Hangzhou, 310018, Zhejiang, China.
Xiaoling ZhengNMPA Key laboratory for Testing and Risk Warning of Pharmaceutical Microbiology, Biological Inspection Department, Zhejiang Institute for Food and Drug Control, Hangzhou, 310052, Zhejiang, China.
Chao LiuDepartment of Orthopaedics, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China. liuchaozju@zju.edu.cn.
Huan ChenKey laboratory of Microbial technology and Bioinformatics of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou, 310012, Zhejiang, China. chenhuan7809@gmail.com.
Institute of Microbiology · CNZheJiang Institute For Food and Drug Control · CNZhejiang University · CNZhejiang University-University of Edinburgh Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSafety issues of probiotic products have been reported frequently in recent years. Ten bacterial strains isolated from seven commercial probiotic products on market were evaluated for their safety, by whole-genome analysis.

resultsWe found that the bacterial species of three probiotic products were incorrectly labeled. Furthermore, six probiotic product isolates (PPS) contained genes for the production of toxic metabolites, while another three strains contained virulence genes, which might pose a potential health risk. In addition, three of them have drug-resistance genes, among which two strains potentially displayed multidrug resistance. One isolate has in silico predicted transferable genes responsible for toxic metabolite production, and they could potentially transfer to human gut microflora or environmental bacteria. Isolates of Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis are associated with low risk for human consumption. Based on a comparative genome analysis, we found that the isolated Enterococcus faecium TK-P5D clustered with a well-defined probiotic strain, while E. faecalis TK-P4B clustered with a pathogenic strain.

conclusionsOur work clearly illustrates that whole-genome analysis is a useful method to evaluate the quality and safety of probiotic products. Regulatory quality control and stringent regulations on probiotic products are needed to ensure safe consumption and protect human health.

Indexed as

Enterococcus faeciumProbioticsAnti-Bacterial AgentsDrug Resistance, BacterialHumansVirulence FactorsAnti-Bacterial AgentsVirulence FactorsAntimicrobial resistanceHealth riskInstabilityProbioticWhole genome analysis

Identifiers

PMID33761872
PMCPMC7988973
OpenAlexW3137748009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.